Why the study?
PE carries significant impending morbidity and mortality, making the choice of initial anticoagulation that allows for therapeutic adjustment important.
This review highlights that while DOACs are generally preferred for post-PE anticoagulation, specific patient populations require tailored approaches using VKAs or LMWH.
DOACs may be preferred for most PE patients; leaves open optimal choices in special populations.
Pulmonary embolus (PE) carries a significant impending morbidity and mortality, especially in intermediate and high-risk patients, and the choice of initial anticoagulation that allows for therapeutic adjustment or manipulation is important. The preferred choice of anticoagulation management includes direct oral anticoagulants. Vitamin K antagonists and low-molecular-weight heparin are preferred in special populations or selected patients such as breastfeeding mothers, those with end-stage renal disease, or obese patients, among others. This article reviews the primary and longer-term considerations for anticoagulation management in patients with PE and highlights special patient populations and risk factor considerations.
No takes yet. Share an insight, caveat, or question.
Joseph J. Naoum (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: